Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TAS2R8 | Q9NYW2 | 13/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20138234 | 0.76 | TSHR (0.39) | HSD17B10TSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL2204904 | 0.65 | TDP1 (0.65) | HSD17B10TSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21672067 | 0.60 | REN (0.34) | — | |
| SCHEMBL20137924 | 0.59 | BRD4 (0.35) | TSHRHTTALDH1A1 | |
| SCHEMBL8570701 | 0.59 | TDP1 (0.52) | HSD17B10TSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL20137910 | 0.58 | TSHR (0.40) | TSHRHTTALDH1A1 | |
| SCHEMBL20138011 | 0.58 | TSHR (0.35) | TSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL20138269 | 0.58 | HDAC1 (0.49) | HSD17B10TSHRHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL20137997 | 0.57 | TSHR (0.37) | TSHRHTTALDH1A1 | |
| SCHEMBL25898322 | 0.57 | MARK3 (0.50) | SMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | HSD17B10 1111/4885TSHR 2169/4885HTT 303/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | HSD17B10 2471/4885TSHR 940/4885HTT 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.